Soft Tissue Sarcoma Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.

United statesRichard pazdurOffice of oncologic diseasesNational comprehensive cancer networkOncology centerOncologic diseasesDrug evaluationPractice guidelinesNational comprehensive cancer networkSoft tissue sarcoma guidelinesVersion 3 2023Ategory 1 recommendationPhase 3 defi trial nct03785964